{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T22:57:20Z","timestamp":1793141840412,"version":"4.5.0"},"reference-count":67,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Human Vaccines &amp; Immunotherapeutics"],"published-print":{"date-parts":[[2026,12,31]]},"DOI":"10.1080\/21645515.2026.2675068","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T04:33:06Z","timestamp":1779337986000},"update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":2,"title":["Tebentafusp (IMCgp100), a first in class immune-mobilizing monoclonal T-cell receptors against cancer (ImmTAC) for HLA-A*02:01 positive uveal melanoma: Product review"],"prefix":"10.1080","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8120-3827","authenticated-orcid":false,"given":"Jonathan E.","family":"Cohen","sequence":"first","affiliation":[{"name":"Hadassah-Hebrew University Medical Center","place":["Jerusalem, Israel"]},{"name":"Hadassah-Hebrew University Medical Center","place":["Jerusalem, Israel"]},{"name":"A Cedars-Sinai Affiliate","place":["Los Angeles"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inderjit","family":"Mehmi","sequence":"additional","affiliation":[{"name":"A Cedars-Sinai Affiliate","place":["Los Angeles"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mordechai","family":"Avner","sequence":"additional","affiliation":[{"name":"Hadassah-Hebrew University Medical Center","place":["Jerusalem, Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Moyers","sequence":"additional","affiliation":[{"name":"A Cedars-Sinai Affiliate","place":["Los Angeles"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omid","family":"Hamid","sequence":"additional","affiliation":[{"name":"A Cedars-Sinai Affiliate","place":["Los Angeles"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,5,20]]},"reference":[{"key":"e_1_3_4_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.aopr.2024.10.001"},{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.03-0538"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2020-317949"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz176"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2016.09.008"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16276-8"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709684"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2407417"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-55675-5"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-024-03776-5"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1998.646"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-1198"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13235968"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2502099"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-023-00809-z"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002899"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.labinv.2024.102209"},{"issue":"11","key":"e_1_3_4_19_1","first-page":"4159","article-title":"Major histocompatibility antigens and antigen-processing molecules in uveal melanoma","volume":"9","author":"Krishnakumar S","year":"2003","unstructured":"Krishnakumar S, Abhyankar D, Sundaram AL, Pushparaj V, Shanmugam MP, Biswas J. Major histocompatibility antigens and antigen-processing molecules in uveal melanoma. Clin Cancer Res. 2003;9(11):4159\u20134164.","journal-title":"Clin Cancer Res"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11081132"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2764"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM10-5616"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/nbt1070"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/protein\/gzg087"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-024-00700-2"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-014-1525-z"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/imm.12779"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0205491"},{"key":"e_1_3_4_29_1","volume-title":"Office of Regulatory Affairs BaRDD, Ed.","year":"2022","unstructured":"Summary basis of decision for Kimmtrak. In: Office of Regulatory Affairs BaRDD, Ed.; 2022. https:\/\/dhpp.hpfb-dgpsa.ca\/review-documents\/resource\/SBD00605."},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-1247"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01805"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02015-7"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009028"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102076"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2103485"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2304753"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.9585"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v104.41297"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15133430"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115634"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-53145-0"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2023.102543"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.11.013"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00550"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.e21505"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.115161"},{"key":"e_1_3_4_47_1","volume-title":"NCCN clinical practice guidelines in oncology (NCCN guidelines): uveal melanoma","author":"National Comprehensive Cancer Network","year":"2025","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN guidelines): uveal melanoma. Plymouth Meeting, PA: National Comprehensive Cancer Network; 2025."},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-006747"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.07.854"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-25-1513"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI181464"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.08.037"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2024.03.048"},{"key":"e_1_3_4_54_1","unstructured":"U.S. Food and Drug Administration. Kimmtrak (tebentafusp-tebn) prescribing information. Silver Spring Maryland (MD): U.S. Food and Drug Administration; 2024."},{"key":"e_1_3_4_55_1","unstructured":"Cancer Care Ontario (Ontario Health). Drug formulary monograph: tebentafusp. Toronto ON: Cancer Care Ontario (Ontario Health); 2024."},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.112986"},{"key":"e_1_3_4_57_1","volume-title":"Health CAfDaTi, editor. Canadian Agency for Drugs and Technologies in Health CTI \u2013 CADTH reimbursement reviews and recommendations","author":"Canadian Agency for Drugs and Technologies in Health","year":"2023","unstructured":"Canadian Agency for Drugs and Technologies in Health. Tebentafusp (Kimmtrak): CADTH reimbursement review. In: Health CAfDaTi, editor. Canadian Agency for Drugs and Technologies in Health CTI \u2013 CADTH reimbursement reviews and recommendations. Ottawa, ON: Canadian Agency for Drugs and Technologies in Health (CADTH); 2023. p. 125."},{"key":"e_1_3_4_58_1","unstructured":"National Institute for Health and Care Excellence. Tebentafusp for treating advanced uvealmelanoma. National Institute for Health and Care Excellence; London UK; 2023."},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.38612"},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005600"},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyaf323"},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-024-15293-x"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(25)00720-X"},{"key":"e_1_3_4_64_1","volume-title":"ESMO congress 2025","author":"Kapiteijn E","year":"2025","unstructured":"Kapiteijn E, Van den Hoek L, Speetjens F, Zunder SM, Van Erkel A, Van der Meer R, Van Rijswijk C, Lutjeboer J, Tong TM, Jonker M. Combined percutaneous hepatic perfusion with ipilimumab plus nivolumab in metastatic uveal melanoma (CHOPIN): a single-center, open-label, randomized, phase II study. In: ESMO congress 2025. 2025 Oct 17\u201321; Berlin (Germany): European Society for Medical Oncology (ESMO); 2025."},{"key":"e_1_3_4_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103623"},{"key":"e_1_3_4_66_1","unstructured":"McKean M Chmielowski B Butler MO Carvajal RD Rodon J Carlino MS Kim KB Wise-draper T Khan S Salama AKS et al. First reported overall survival results from a phase 1\/2 study of darovasertib plus crizotinib as first-line treatment for metastatic uveal melanoma (OptimUM-01). In: 2025 Society for Melanoma Research (SMR) Congress; 2025 Oct 25\u201328; Amsterdam Netherlands 2025. https:\/\/www.annalsofoncology.org\/article\/S0923-7534(23)03052-1\/fulltext."},{"key":"e_1_3_4_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.08.2230"},{"key":"e_1_3_4_68_1","volume-title":"Efficacy and safety of IMA203, a PRAME-directed T-cell receptor (TCR) T-cell therapy, in patients with previously treated advanced or metastatic uveal melanoma from a phase I trial. In: ESMO Congress 2025","author":"Patel SP","year":"2025","unstructured":"Patel SP, Tsimberidou AM, Luke JJ, Alsdorf W, Busse A, DeVane SC, Hengler, S, Hilf, N, Kursunel, MA, Mayer-Mokler, A, et al. Efficacy and safety of IMA203, a PRAME-directed T-cell receptor (TCR) T-cell therapy, in patients with previously treated advanced or metastatic uveal melanoma from a phase I trial. In: ESMO Congress 2025. 2025 Oct 17\u201321; Berlin (Germany): European Society for Medical Oncology (ESMO); 2025."}],"container-title":["Human Vaccines &amp; Immunotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/21645515.2026.2675068","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T04:33:25Z","timestamp":1779338005000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/21645515.2026.2675068"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,20]]},"references-count":67,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12,31]]}},"alternative-id":["10.1080\/21645515.2026.2675068"],"URL":"https:\/\/doi.org\/10.1080\/21645515.2026.2675068","relation":{},"ISSN":["2164-5515","2164-554X"],"issn-type":[{"value":"2164-5515","type":"print"},{"value":"2164-554X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,20]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=khvi20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=khvi20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-01-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-24","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"2675068"}}